An interventional study of Avocado and Control in Obesity, Abdominal, Insulin Resistance and Insulin Sensitivity, sponsored by University of Illinois at Urbana-Champaign. Status unknown at 1 site in United States. Open to participants aged 25 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-17.
Sponsored by University of Illinois at Urbana-Champaign · Not applicable, Interventional, and Treatment
The proposed work will investigate the effects of avocados on abdominal obesity and glycemic control among overweight/obese adults.
The proposed work will investigate the effects of avocados on abdominal obesity and glycemic control among overweight/obese adults. Further, changes in GI microbiota composition and cognitive function will be assessed to comprehensively understand systemic benefits of avocado consumption on gut and brain function. This research study has two aims: 1) To determine the effects of regular avocado intake on metabolic syndrome risk factors, specifically, abdominal obesity and glycemic control, among overweight and obese adults; and 2) to investigate the implications of avocado intake on measures of GI microbiota composition and cognitive function.
1,960 studies on the registry are indexed under Insulin Resistance; 306 are open to participants now.
This study's planned enrollment of 200 is above the median of 40 across 1,536 interventional studies indexed under Insulin Resistance.
Browse Insulin Resistance studies →University of Illinois at Urbana-Champaign is the lead sponsor of 188 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intervention meals will contain 1 large avocado and be consumed daily for 12 weeks.
Other: Avocado
Control meals will be isocaloric to the intervention meals but without avocado. They will also be consumed daily for 12 weeks.
Other: Control
The intervention meals will contain 1 large avocado.
The control meals will be isocaloric to the intervention meals but will not contain avocado.
Abdominal obesity
Changes to abdominal and whole body composition including visceral and subcutaneous adipose tissue will be estimated by DEXA.
Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks
Glycemic Control
Glycemic control will be assessed using oral glucose tolerance tests and hemoglobin A1c.
Time frame: Baseline, 4 weeks, 8 weeks,12 weeks
Insulin Resistance
Insulin resistance will be evaluated using the Homeostasis Assessment Model (HOMA) index.
Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks
Insulin Sensitivity
Insulin sensitivity will be assessed using the insulinogenic index, Stumvoll Metabolic Clearance Rate, Oral Glucose Insulin Sensitivity, and the Matsuda Index.
Time frame: Baseline, 12 weeks
Gastrointestinal Microbiota Composition and Short Chain Fatty Acids
Microbial taxonomy will be assessed using high throughput sequencing and short chain fatty acids will be quantified using gas chromatography and mass spectrometry.
Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks
Cognitive Function
Cognitive function will be evaluated using tasks that measure prefrontal cognitive control and hippocampal relational memory networks.
Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks
Retinal Lutein
Retinal lutein will be assessed using Macular Pigment Optical Density.
Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks
Serum Lutein
Serum lutein will be assessed using venous blood samples.
Time frame: Baseline, 12 weeks
Blood Lipid Panel
Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides will be assessed using venous blood samples.
Time frame: Baseline, 12 weeks
Resting Energy Expenditure
REE will be measured by indirect calorimetry.
Time frame: Baseline, 12 weeks
Neuroelectric Assessment
A Neuroelectric Assessment will be conducted during cognitive tasks using an Electroencephalogram (EEG) amplifier.
Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks
DNA Analyses
Genetic markers related to obesity and cognitive function will be assessed using blood samples to determine the mediating effects of genetics on changes related to study outcomes.
Time frame: Baseline
Dietary Intake
Dietary intake will be evaluated using 7 day diet records at baseline, 4, 8, and 12 weeks and by NCI NHANES 30-day food frequency questionnaires at baseline and 12 weeks.
Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks
Sleep and Fatigue
Sleep and fatigue will be evaluated using the Pittsburgh Sleep Quality Index
Time frame: Baseline, 12 weeks
Physical Activity
Physical activity will be measured over 7 day periods by a waist mounted accelerometer.
Time frame: Baseline, 12 weeks
Blood Pressure
Blood pressure will be measured using an automatic blood pressure cuff.
Time frame: Baseline, 12 weeks
Liver Enzymes
Liver enzymes will be assessed using venous blood samples.
Time frame: Baseline, 12 weeks
Inflammatory Markers
Markers of inflammation such as c-reactive protein (CRP) will be assessed using venous blood samples.
Time frame: Baseline, 12 weeks
This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Illinois at Urbana-Champaign